Although there have been significant advances in the identification of biomarkers of Alzheimer's disease (AD), comorbidity is a common finding at autopsy and the neuropathologic assessment at autopsy remains the gold standard for diagnosis.
The aims of the Neuropathology Core (Core D) will be: (1) To make neuropathologic diagnoses on all new brain accessions from HASD research participants using standard diagnostic criteria;(2) To perform brain autopsies and to collect, store at -80?C, and distribute formalin-fixed, paraffin-embedded, and frozen brain tissue samples to support HASD Projects and investigators and outside collaborations that enhance HASD research goals;(3) To support Projects 1 and 2 by providing a neuropathologic assessment and quantitative measures of the molecular pathology (beta- amyloidosis, tauopathy, synucleinopathy, and TDP-43 proteinopathy) of cases which come to autopsy. To support the Specific Aims of Project 3 by providing neuropathologic data, quantitative measures of the molecular pathology, and tissue (for mRNA and DNA extraction) relating to cases recruited for the study of genetic variants and their influence on the progression of AD (4) To maintain a computerized neuropathology database (CaTissue) in concert with the Biostatistics Core (Core C) and the Clinical Core (Core B) and the Washington University Neuroscience Blueprint Interdisciplinary Center Core (P30 NS057105). Information stored will include macroscopic images of fresh and fixed brain, demographic data, diagnoses, semi- quantitative morphometric data, neuropathology reports in collaboration with Dr. Perrin, bibliographic information, and data relevant to Core tissue banking activities. If acceptable, neuropathology data also will be transferred, after Biostatistics Core quality control and validation, to the National Alzheimer Coordinating Center (NACC), University of Washington, Seattle, WA (U01 AG016976);(5) To undertake a developmental clinico-biomarker-neuropathologic study of HASD participants to determine the progression of biomarker changes in longitudinally assessed participants who transition from preclinical AD to symptomatic AD and who come to autopsy. Neuropathology will be the benchmark against which biomarker (CSF A?42 and pTau and PET-amyloid imaging) data will be assessed. With the Imaging and Biostatistics Cores and Projects 1 and 2, Core D will explore the contribution of AD biomarker changes with neuropathologic data including measures of A? and pTau burden, synaptic and neuronal loss.

Public Health Relevance

Core D: Neuropathology Project Narrative As instructed by the funding opportunity announcement for this application (PAR-13-329), only the Overall component contains a project narrative. Cores and projects were instructed not to include this section.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Saint Louis
United States
Zip Code
Adel, Tameem; Cohen, Taco; Caan, Matthan et al. (2017) 3D scattering transforms for disease classification in neuroimaging. Neuroimage Clin 14:506-517
Schindler, Suzanne E; Jasielec, Mateusz S; Weng, Hua et al. (2017) Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. Neurobiol Aging 56:25-32
Zhao, Yue; Raichle, Marcus E; Wen, Jie et al. (2017) In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. Neuroimage 148:296-304
Su, Yi; Vlassenko, Andrei G; Couture, Lars E et al. (2017) Quantitative hemodynamic PET imaging using image-derived arterial input function and a PET/MR hybrid scanner. J Cereb Blood Flow Metab 37:1435-1446
Deming, Yuetiva; Li, Zeran; Kapoor, Manav et al. (2017) Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. Acta Neuropathol 133:839-856
Day, Gregory S; Lim, Tae Sung; Hassenstab, Jason et al. (2017) Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology 88:1273-1281
Monsell, Sarah E; Mock, Charles; Fardo, David W et al. (2017) Genetic Comparison of Symptomatic and Asymptomatic Persons With Alzheimer Disease Neuropathology. Alzheimer Dis Assoc Disord 31:232-238
Mez, Jesse; Chung, Jaeyoon; Jun, Gyungah et al. (2017) Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans. Alzheimers Dement 13:119-129
Khajehnejad, Moein; Saatlou, Forough Habibollahi; Mohammadzade, Hoda (2017) Alzheimer's Disease Early Diagnosis Using Manifold-Based Semi-Supervised Learning. Brain Sci 7:
Holth, Jerrah; Patel, Tirth; Holtzman, David M (2017) Sleep in Alzheimer's Disease - Beyond Amyloid. Neurobiol Sleep Circadian Rhythms 2:4-14

Showing the most recent 10 out of 831 publications